CD8A and myeloid sarcoma: A notable observation was the presence of the STAT3*D661Y mutation in the CD8 + subpopulation of an MS patient, at an allelic fraction of 0.45% upon discovery and 0.74% in follow-up 19 months later (Table 3, Table S6).